Evaluation of a new antihelminthic for trichuriasis, hookworm, and stronglyloidiasis.
Mebendazole was tested in a double-blind trial for its efficacy in the treatment and control of enteric helminths. One hundred and twenty-two children from a community near the Gulf of Carpentaria, and from a community in Cape York Peninsula in northern Queensland were divided into two equal groups to receive a course of either mebendazole or placebo after the identification of one or more intestinal helminths in a single pretreatment specimen of faeces. Between the tenth and twentieth days after a four-day course of treatment, three specimens of faeces were collected from each child. Mebendazole cured trichuriasis in 75% of cases, and over-all egg reduction rate was 96%. The drug also cured hookworm in 13 out of 15 cases and Strongyloides sterocoralis infestation in 14 out of 21 cases. Mebendazole was ineffective against Hymenolepis nana. No cases of Ascaris lumbricoides infestation were present. No side effects or adverse reactions to the drug were noted and patient acceptance was excellent. Mebendazole appears to be a safe drug for use in the treatment of human parasitic intestinal nematode infestations, and should be especially useful in the treatment and control of trichuriasis.
D000293:Adolescent; D000723:Ancylostomatoidea / Q000187:drug effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006725:Hookworm Infections / Q000188:drug therapy*; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy*; D008463:Mebendazole / Q000494:pharmacology / Q000627:therapeutic use*; D010270:Parasite Egg Count; D013321:Strongyloides / Q000187:drug effects; D013322:Strongyloidiasis / Q000188:drug therapy*; D014257:Trichuriasis / Q000188:drug therapy*; D014258:Trichuris / Q000187:drug effects
D001562:Benzimidazoles; D008463:Mebendazole